Close search box Search

Oxford Cannabinoid Technologies

Unlocking the medical potential of cannabinoids




NewCo Establishment


Life Sciences

OCT is a next generation cannabinoid-based pharmaceutical firm

Investment Highlights

  • Whilst changes in legislation have resulted in the creation of cannabis markets across the world, there remains a market opportunity for the development of cannabinoid-based licensed medicines
  • OCT’s vision is to become a global leader in cannabinoid prescription medicine, working with world-class partners on research and development, developing medication that improves the quality of life for patients
  • Kingsley founded OCT after agreeing a research partnership with Oxford University. Since then, the company has completed several rounds of funding, including from FTSE 100 company Imperial Brands PLC. In May 2021, OCT completed an IPO on the Main Market of the London Stock Exchange
  • OCT has a lead compound in development for several indications, along with a library of over 400 cannabinoid derivative compounds, both developed internally and licensed from cannabis conglomerate Canopy Growth corporation
  • In May 2021, OCT completed an IPO on the Main Market of the London Stock Exchange

The foresight of Kingsley – to invest significant resources and capital in such a progressive market – is enabling us to undertake world-class research in state-of-the-art facilities, led by experts in the field. All of which will help develop new therapies for patients whose needs are not yet met.

Dr. John Lucas
Chief Executive Officer

OCT Press Releases

Oxford Cannabinoid Technologies